About

CEO Statement

“Neovacs’ unique approach allows us to produce innovative treatments intended to be curative and accessible to all patients suffering from autoimmune diseases. Beyond product development, in order to ensure the production of its technology, Neovacs also operates Neostell, a production site for all of the company’ Kinoids®. To support our research work, we have assembled a team of leading international specialists. Our hope is that these investments will produce the emergence of treatments that will make a substantial difference in healthcare.”

Members

MIGUEL SIELER (Chief Executive Officer)

miguel-sieler

Miguel Sieler brings over 32 years experience in the pharmaceutical and chemical industry.
Miguel Sieler joined Bayer AG, Leverkusen, (Germany) in 1975 for an international career which started at the group headquarters in Germany. He further served in various senior management positions in Brussels and Sao Paulo before becoming President of Bayer in Korea, followed by 4 years as C.E.O of Bayer Pharma France. In 1998, Miguel Sieler became Chairman and C.E.O of the Bayer Group in France.  Miguel Sieler holds a Master of Law from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France.

 

BERNARD FANGET (Vice President Pharmaceutical Development)

bernard-fanget

He joined Neovacs in 2005, he was previously Senior –VP- PD, of Flamel Technologies and previously Corporate VP, Global Industrialization, at Sanofi Pasteur.

Degree in biological chemistry from the University of Lyon, France

 

OLIVIER DHELLIN (Director, Pharmaceutical Development and Quality Assurance)

oliv

He joined Neovacs in 2005.

Previously Head of CMC at Anosys and research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute. Degree in Pharmacy (Paris XI University, France) and a PhD in Virology (Pierre et Marie Curie University, France).

 

VALÉRIE SALENTEY (PharmD, Head of Regulatory Affairs)

Photo_V.Salentey

Valérie joined Neovacs in 2018. Previously, she was Senior Regulatory Affairs Manager at PPD, Clinical Trials Regulatory Affairs Manager at Genethon, Regulatory Affairs and Quality Assurance Manager at Cytheris.

Degree in Pharmacy (Paris V and Lyon I University, France)

VINCENT SERRA (Chief Scientific Officer)

vincent serra CSO

He joined Neovacs in 2019. He previously worked at Pierre Fabre as Head of External Innovation and Executive manager of the Pierre Fabre innovation Fund.

CSO, CEO and cofounder of different biotech companies (Anosys, Wittycell, Abivax). He is an optimization expert in innovative cycle, from the early identification of molecules with high potential for value creation with a patient benefice. He has authored several patents, scientific publications in peer-reviewed journals and chapter book in the vaccine fields.

PhD in immunology from the University of Grenoble, France.

Dr. Virginia Pascual, MD 

Virginia Pascual MD

Dr. Virginia Pascual joins Neovacs as Scientifi and Medical Advisor.

She is also the Founding Director of the Gale and Ira Drukier Institute for Children’s Health at Weill Cornell Medicine in New York City. Her research work has been published in many prestigious scientific revues, she has received multiple awards for her discoveries, from the National Institute of Allergy & Infectious Diseases, and in 2017 the “Lupus Insight Prize” for highly promising research into understanding the events leading to lupus flares. Before joining the Drukier Institute in New York, Dr Pascual served at the Baylor Institute for Immunology Research in Dallas as Director of the Centre for Inflammation and Genomics. She received her medical degree at the Universidad Complutense in Madrid and specialised in pediatric rheumatology at UT Southwestern Medical Center in Dallas, TX.

Nous retrouver

NEOVACS S.A.

3-5, Impasse Reille

75014 PARIS

FRANCE

 

Tel. : 33 (0)1 53 10 93 00

Fax : 33 (0)1 53 10 93 03

POURQUOI INVESTIR ?

VOIR L’ESPACE INVESTISSEURS